Dennis Miller, R.Ph. is a retired chain store pharmacist. His book, The Shocking Truth About Pharmacy: A Pharmacist Reveals All the Disturbing Secrets, can be downloaded in its entirety at Amazon for 99 cents.
A Profitable Failure of Imagination
Modern cancer care is often presented as a heroic struggle: white coats, infusion chairs, miracle drugs, fundraising walks, and solemn advertising campaigns promising hope. Much of that care is lifesaving, and many clinicians act with skill and compassion. But the system around them deserves a far more hostile examination.
In a society saturated with industrial chemicals, pesticides, plastics, solvents, flame retardants, petrochemical byproducts, air pollutants, and occupational exposures, cancer is not only a biological disaster. It is also an economic event. Once a person becomes sick, an enormous commercial machine activates: hospitals bill, insurers negotiate, pharmaceutical companies sell, advertisers recruit, device makers supply, laboratories test, consultants manage, and investors watch.
The question is not whether doctors secretly want cancer. That caricature misses the point. The real issue is structural: a treatment-centered cancer economy can flourish even while the political will to prevent carcinogenic exposure remains weak.
The Chemical Background Noise of Daily Life
The link between environmental exposures and cancer is not fringe speculation. The National Cancer Institute notes that some cancer-causing genetic changes result from environmental exposures, including chemicals in tobacco smoke and other substances encountered through air, water, food, workplaces, and daily materials. It also emphasizes that some exposures are hard to avoid precisely because they are embedded in ordinary life.
Public health authorities have identified many substances and exposure circumstances as known or reasonably anticipated human carcinogens, including asbestos, benzene, formaldehyde, ethylene oxide, hexavalent chromium compounds, vinyl chloride, trichloroethylene, soot, diesel exhaust, and others. The International Agency for Research on Cancer has evaluated more than 1,000 agents and classified hundreds as carcinogenic, probably carcinogenic, or possibly carcinogenic to humans.
That does not mean every exposure inevitably causes cancer. Dose, duration, timing, genetics, and combined exposures matter. But it does mean the chemical environment is not a neutral backdrop. It is a field of risk, unevenly distributed and often involuntary.
Downstream Medicine, Upstream Silence
The dominant cancer model is downstream. Detect the tumor. Stage it. Cut it, burn it, poison it, or target it. Bill for each step. Celebrate survival when possible. Mourn failure when treatment comes too late.
Upstream prevention asks a different and more threatening question: why are so many carcinogenic or suspicious substances allowed to circulate through workplaces, consumer goods, food systems, packaging, buildings, neighborhoods, and waste streams in the first place?
That question threatens powerful interests because prevention is not simply a medical project. It is a regulatory, industrial, agricultural, labor, housing, and environmental project. It requires banning, substituting, redesigning, monitoring, enforcing, and compensating. It requires making polluters pay before patients do.
The Revenue Logic of Treatment
Cancer treatment is financially immense. Care may involve imaging, pathology, surgery, chemotherapy, radiation, immunotherapy, targeted drugs, genetic testing, hospital stays, emergency visits, pain management, monitoring, rehabilitation, and end-of-life care. Each component has a price. Each price has a beneficiary.
The projected national cost of cancer care in the United States has been estimated in the hundreds of billions of dollars by 2030. Those costs devastate many families, but they also form revenue streams for sectors that have adapted to cancer as a recurring market.
Chemotherapy, in particular, symbolizes the treatment-first worldview. It can be medically appropriate and lifesaving in many cases. Yet as a social priority, chemotherapy also represents a grim bargain: allow dangerous exposures to persist, then mobilize extraordinary resources once bodies begin to fail.
Who Benefits from the Status Quo?
The beneficiaries are not a single cabal. They are an ecosystem. Pharmaceutical firms benefit from high-priced oncology drugs. Hospitals benefit from infusion centers, surgeries, admissions, and specialty services. Insurers benefit from their role as toll collectors and negotiators in a complex payment system. Pharmacy benefit managers, specialty pharmacies, billing contractors, consultants, and advertising firms all feed from the stream.
Meanwhile, chemical manufacturers, plastics producers, agribusiness firms, fossil-fuel interests, and industrial users benefit when the burden of proof remains slow, fragmented, and expensive. They can argue uncertainty. They can lobby against restrictions. They can fund doubt. They can demand more studies while exposure continues.
The result is a perverse alignment. The industries that may contribute to exposure are rarely forced to absorb the full downstream medical costs, while the industries that treat disease profit after the fact. The patient is left in the middle, biologically harmed and financially harvested.
Advertising Hope While Avoiding Cause
Cancer advertising is often emotionally polished. It shows brave patients, caring institutions, advanced technologies, and language of battle, hope, and innovation. What it rarely shows is a chemical plant, a refinery corridor, a polluted aquifer, a warehouse of treated materials, or a worker inhaling solvents over decades.
The preferred story begins at diagnosis, not exposure. It begins when the patient enters the medical marketplace, not when society approved the products, emissions, ingredients, and occupational conditions that may have contributed to risk.
This narrative is convenient. It individualizes disease, medicalizes the response, and converts political failure into personal tragedy. Prevention becomes a ribbon. Treatment becomes an industry.
The Politics of “More Research”
Science matters. Evidence matters. False certainty is dangerous. But “more research” can also become a political sedative. When the standard for action is near-absolute proof of harm, industries gain decades of profitable delay.
Carcinogenesis is difficult to study because cancers may develop years after exposure, people encounter mixtures rather than single substances, and poorer communities often face higher exposure while having less political power. These difficulties should strengthen precaution, not paralyze it.
If regulators wait until every causal pathway is perfectly mapped, the public becomes the experiment. The profits are private. The tumors are public.
The Class Geography of Exposure
Exposure is not distributed democratically. Workers in factories, agriculture, firefighting, construction, transportation, military service, waste handling, and industrial cleaning may encounter carcinogens more directly than executives and shareholders. Low-income neighborhoods are more likely to sit near highways, refineries, waste sites, ports, and aging infrastructure.
This is where the cancer economy becomes morally obscene. The people least able to avoid exposure are often least able to afford treatment. They breathe the risk, drink the risk, work in the risk, and then face the bills.
What Real Prevention Would Require
Real prevention would not mean abandoning treatment. People who are sick need the best care available. But a humane society would treat chemotherapy as a last line of defense, not the centerpiece of cancer policy.
Prevention would mean stronger chemical testing before market approval, faster removal of known carcinogens, transparent labeling, workplace protections, pollution enforcement, independent research funding, biomonitoring, safer substitutes, and legal accountability for companies that externalize disease costs.
It would also mean changing incentives. Public money should reward exposure reduction, not merely late-stage intervention. Hospitals and insurers should be judged not only by treatment throughput but by community health outcomes. Corporations should not be allowed to profit from risky products while society pays for the oncology ward.
The Uncomfortable Bottom Line
The modern cancer system is brilliant at monetizing disease and timid at challenging the conditions that help produce it. Its greatest achievements are real, but so are its evasions. A society that pours wealth into chemotherapy while tolerating preventable carcinogenic exposure is not merely treating cancer. It is managing a profitable failure.
The deeper scandal is not that medicine treats cancer. It must. The scandal is that prevention remains politically weaker than profit, and that the chemical status quo is protected by the very complexity of proving harm. Until society confronts the upstream sources of exposure with the same urgency it brings to tumors, the cancer economy will continue to thrive.
The humane goal is not less treatment for patients. It is fewer patients needing treatment. That goal threatens revenue, disrupts industry, and forces elites to answer for the world they have built. Which is exactly why it matters.
Dennis Miller, R.Ph. is a retired chain store pharmacist. His book, The Shocking Truth About Pharmacy: A Pharmacist Reveals All the Disturbing Secrets, can be downloaded in its entirety at Amazon for 99 cents.
